Natco Pharma Articles

Indian patent appeal board upholds compulsory license on Bayer's Nexavar

5 March 2013

Another negative Indian patent ruling, this time for Pfizer's Sutent

8 October 2012

India's IPAB rejects Bayer's "stay petition" regarding Nexavar

18 September 2012

Indian hearings on Bayer Nexavar compulsory license delayed

22 August 2012

News briefs: Copaxone patent ruling; German Sativex backing; Depomed licenses Zipsor

24 June 2012

India issues compulsory license for Bayer cancer drug Nexavar

13 March 2012

Natco in biogenerics in deal with Mabxience; plans generic launches in South Africa

6 November 2011

Sth Africa’s Litha Healthcare teams with Natco for generics marketing in India

25 September 2011

Teva prevails in Copaxone law suit with Mylan/Natco and Sandoz/Momenta

30 August 2011

Natco joins forces with Lupin to sell generic Tykerb; gets orphan status for cancer drug candidate

24 June 2011

UCB and PDL settle patent disputes over Cimzia; Natco challenges Gilead’s Tamiflu

8 February 2011

Watson confirms deal with Natco for generic version of Celgene’s cancer drug Revlimid

8 December 2010

India’s Natco challenges Celgene’s Revlimid patent in USA; new CFO named

6 September 2010

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end